Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality - Amgen

Patients

December 2024

Summary

Global patterns in hip fractures: trends in occurrence, treatment, and survival

By accessing de-identified patient data from 19 countries, Amgen, in partnership with international researchers, investigated global trends in hip fracture incidence, treatment, and deaths in patients aged 50 and over. 

Amgen

About this study

Fractures relating to weak and brittle hip bones are placing an ever-greater burden on healthcare systems across the world. This study looked at 20 international health databases from 19 countries, including the Clinical Practice Research Datalink (CPRD) in the UK,  to provide a detailed analysis of hip fracture trends across various regions, age groups, and populations.

This study highlights hip fractures as a significant global public health issue associated with high occurrence in the population and increased risk of death. Although incidence rates have declined in many countries, global population ageing is expected to nearly double the total number of fractures in the next 20 to 30 years. The study also uncovered that men were less likely to receive treatment that would reduce the risk of fractures reoccurring.

Data sources used:

• 20 International patient data records: recording patient admissions to hospital 12 databases captured over 90% of their respective country or region’s population, while the remaining eight covered 5% to 70%.

• Clinical Practice Research Datalink: a comprehensive UK database containing anonymised electronic health records from over 21 million patients, capturing demographic information, diagnoses, drug exposures, and other medical data.

Benefits of the study

The study accessed data relating to patients’ hospital admittance to identify: differences between countries and regions, estimate the future hip fracture burden, and highlight treatment gaps and variations in post-fracture care.

The inclusion of databases covering countries in Oceania, Asia, Europe, and the Americas ensured a representative global perspective and that the findings would be beneficial for all healthcare providers. Without the access to data from other countries, healthcare systems would not be able to identify areas of improvement in the care of hip fractures that need to be addressed.  Through the data used in this study, Amgen were able to highlight which regions performed better.  

In the future, the findings from this study will contribute to the development of improved prevention and management strategies to address the growing burden and cost of treating hip fractures, particularly for men.  
 

Further information

Read the clinical study

Last modified: 15 February 2025

Last reviewed: 15 February 2025